T‑Cells from HLA-B57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms

Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to...

Full description

Saved in:
Bibliographic Details
Published inChemical research in toxicology Vol. 26; no. 5; pp. 759 - 766
Main Authors Bell, Catherine C, Faulkner, Lee, Martinsson, Klara, Farrell, John, Alfirevic, Ana, Tugwood, Jonathan, Pirmohamed, Munir, Naisbitt, Dean J, Park, B. Kevin
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 20.05.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself.
AbstractList Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself.Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself.
Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different V beta receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself.
Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself.
Author Naisbitt, Dean J
Farrell, John
Alfirevic, Ana
Park, B. Kevin
Pirmohamed, Munir
Bell, Catherine C
Faulkner, Lee
Martinsson, Klara
Tugwood, Jonathan
AuthorAffiliation University of Liverpool
The University of Manchester
AuthorAffiliation_xml – name: University of Liverpool
– name: The University of Manchester
Author_xml – sequence: 1
  givenname: Catherine C
  surname: Bell
  fullname: Bell, Catherine C
– sequence: 2
  givenname: Lee
  surname: Faulkner
  fullname: Faulkner, Lee
– sequence: 3
  givenname: Klara
  surname: Martinsson
  fullname: Martinsson, Klara
– sequence: 4
  givenname: John
  surname: Farrell
  fullname: Farrell, John
– sequence: 5
  givenname: Ana
  surname: Alfirevic
  fullname: Alfirevic, Ana
– sequence: 6
  givenname: Jonathan
  surname: Tugwood
  fullname: Tugwood, Jonathan
– sequence: 7
  givenname: Munir
  surname: Pirmohamed
  fullname: Pirmohamed, Munir
– sequence: 8
  givenname: Dean J
  surname: Naisbitt
  fullname: Naisbitt, Dean J
– sequence: 9
  givenname: B. Kevin
  surname: Park
  fullname: Park, B. Kevin
  email: bkpark@liv.ac.uk
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23541086$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-96946$$DView record from Swedish Publication Index
BookMark eNqF0ktv1DAQAGALFdEHHPgDyBckEIRO7DiP3sIW2EpbgcSCuFmO43S9SuLgR5e98RcQ_5Bfglfb9oAqcbEP8834MXOMDkYzKoSepvAmBZKe-h8ZAOQwPUBHKSOQMEjhAB1BWdGEkPLbITp2bg2QRl48QoeEsiyFMj9Cv5d_fv6aqb53uLNmwPNFnbxlxRmkr_A8DGLEn0OzVtI7XFuFa-n1tfCqxRvtV7huhBTX2mK_siZcrfByY_DF2KpJxWX0-JPwq43YOizGdhcIUuHdafhcxQhutvgy9F5PvcKXSq7EqN3gHqOHneidenKzn6Av798tZ_Nk8fHDxaxeJIKWzCeN7BqAouiaHDqZtaxljEpS0lJWknSKCegUqRrSiiwj0JCOgigEKQVtJWVAT9DrfV23UVNo-GT1IOyWG6H5uf5ac2OveK8Dr_IqyyN_seeTNd-Dcp4P2sn4GDEqExyPP5_RihVx_S-ljGZFHlsV6bMbGppBtXeXuG1RBKd7IK1xzqqOS-2F12b0Vuiep8B3Q8DvhiBmvPwn47boffb53grp-NoEO8Yfv8f9BYvfvio
CitedBy_id crossref_primary_10_1021_acs_chemrestox_2c00090
crossref_primary_10_1021_acs_chemrestox_9b00327
crossref_primary_10_1021_acs_chemrestox_6b00333
crossref_primary_10_1016_j_toxlet_2013_10_036
crossref_primary_10_1016_j_iac_2014_04_009
crossref_primary_10_1111_all_14127
crossref_primary_10_1111_all_15814
crossref_primary_10_1038_s42003_021_02657_2
crossref_primary_10_1111_cea_14423
crossref_primary_10_1371_journal_pcbi_1009151
crossref_primary_10_1016_j_coi_2016_05_003
crossref_primary_10_1007_s00204_017_2112_9
crossref_primary_10_1093_toxsci_kfz007
crossref_primary_10_1093_toxsci_kfw177
crossref_primary_10_1146_annurev_pharmtox_052120_014115
crossref_primary_10_1021_acs_chemrestox_4c00262
crossref_primary_10_1111_all_14057
crossref_primary_10_1093_toxsci_kfaa157
crossref_primary_10_1016_j_tox_2021_152971
crossref_primary_10_1111_all_13769
crossref_primary_10_1097_ACI_0000000000000913
crossref_primary_10_1021_ol4036566
crossref_primary_10_1097_ACI_0000000000000834
crossref_primary_10_3987_COM_15_13350
crossref_primary_10_1155_2018_5163129
crossref_primary_10_1093_toxsci_kfw218
crossref_primary_10_4049_jimmunol_1302306
crossref_primary_10_1080_17425255_2018_1441285
crossref_primary_10_1080_03602532_2020_1800725
crossref_primary_10_1155_2016_9520361
crossref_primary_10_1172_JCI99321
crossref_primary_10_1021_acs_chemrestox_6b00393
crossref_primary_10_1039_C4CC06632D
crossref_primary_10_1021_tx400406p
crossref_primary_10_3389_fimmu_2020_01037
crossref_primary_10_1097_QAD_0000000000000867
crossref_primary_10_1111_tan_13183
crossref_primary_10_3389_fimmu_2021_658593
crossref_primary_10_1248_yakushi_21_00120
crossref_primary_10_1021_tx400041v
crossref_primary_10_1016_j_dmpk_2016_11_003
crossref_primary_10_1080_2162402X_2018_1538436
crossref_primary_10_1016_j_biopha_2023_115241
crossref_primary_10_1517_17425255_2015_992780
crossref_primary_10_1007_s00044_023_03091_1
crossref_primary_10_1039_C4TX00238E
crossref_primary_10_1111_cea_14235
crossref_primary_10_1016_j_jdermsci_2017_08_007
crossref_primary_10_1097_DAD_0000000000000439
Cites_doi 10.1086/504874
10.1038/ng.379
10.1038/sj.tpj.6500458
10.1021/pr100967v
10.4049/jimmunol.1003409
10.1073/pnas.0307067101
10.1073/pnas.261581498
10.1016/j.jaci.2009.10.031
10.1002/eji.201142159
10.1097/00002030-200501030-00014
10.1016/S0149-2918(01)80132-6
10.1007/BF03256308
10.1371/journal.pone.0028323
10.1097/00002030-200211080-00017
10.1097/QAD.0b013e328355fe8f
10.1016/S0009-2797(02)00059-5
10.1073/pnas.1207934109
10.1038/ng.632
10.1038/nature11147
10.1056/NEJMoa1009717
10.1177/135965350801300202
10.1038/428486a
10.1186/gm350
10.1111/j.1600-065X.2012.01147.x
10.1016/j.immuni.2008.04.020
10.1016/j.jaci.2006.12.617
10.1056/NEJMoa0706135
10.1073/pnas.0409500102
10.1016/S0140-6736(02)07873-X
ContentType Journal Article
Copyright Copyright © 2013 American Chemical Society
Copyright_xml – notice: Copyright © 2013 American Chemical Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7U7
C1K
ADTPV
AOWAS
DG8
DOI 10.1021/tx400060p
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Toxicology Abstracts
Environmental Sciences and Pollution Management
SwePub
SwePub Articles
SWEPUB Linköpings universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Toxicology Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList MEDLINE - Academic
Toxicology Abstracts


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-5010
EndPage 766
ExternalDocumentID oai_DiVA_org_liu_96946
23541086
10_1021_tx400060p
a039200216
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Medical Research Council
  grantid: G0700654
GroupedDBID -
29B
4.4
55A
5GY
5RE
7~N
AABXI
ABFLS
ABMVS
ABPTK
ABUCX
ACGFS
ACJ
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
EBS
ED
ED~
EJD
F5P
GNL
IH9
IHE
JG
JG~
LG6
P2P
ROL
TN5
UI2
UPT
VF5
VG9
W1F
X
YZZ
---
-~X
5VS
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ADHLV
AGXLV
AHGAQ
BAANH
CITATION
CUPRZ
GGK
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7U7
C1K
.GJ
.HR
1WB
53G
ABHMW
ACRPL
ADNMO
ADTPV
AEYZD
AGQPQ
ANPPW
ANTXH
AOWAS
DG8
RNS
ZGI
ID FETCH-LOGICAL-a385t-bcfb0077fb60fc4d5d553c2838c9c2fe5a0fe29b2da4420b2f30a7a28a3dc3503
IEDL.DBID ACS
ISSN 0893-228X
1520-5010
IngestDate Thu Aug 21 06:30:19 EDT 2025
Fri Jul 11 02:41:58 EDT 2025
Fri Jul 11 01:45:56 EDT 2025
Mon Jul 21 05:30:34 EDT 2025
Thu Apr 24 22:51:24 EDT 2025
Tue Jul 01 03:45:20 EDT 2025
Thu Aug 27 13:42:09 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a385t-bcfb0077fb60fc4d5d553c2838c9c2fe5a0fe29b2da4420b2f30a7a28a3dc3503
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 23541086
PQID 1353476520
PQPubID 23479
PageCount 8
ParticipantIDs swepub_primary_oai_DiVA_org_liu_96946
proquest_miscellaneous_1524395724
proquest_miscellaneous_1353476520
pubmed_primary_23541086
crossref_citationtrail_10_1021_tx400060p
crossref_primary_10_1021_tx400060p
acs_journals_10_1021_tx400060p
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
ACJ
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-05-20
PublicationDateYYYYMMDD 2013-05-20
PublicationDate_xml – month: 05
  year: 2013
  text: 2013-05-20
  day: 20
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Chemical research in toxicology
PublicationTitleAlternate Chem. Res. Toxicol
PublicationYear 2013
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Chessman D. (ref9/cit9) 2008; 28
Lu J. V. (ref27/cit27) 2012; 249
Wu Y. (ref15/cit15) 2007; 119
Thomas D. A. (ref24/cit24) 2001; 98
Martin A. M. (ref18/cit18) 2005; 19
Chung W. H. (ref17/cit17) 2004; 428
Adam J. (ref11/cit11) 2012; 42
Walsh J. S. (ref29/cit29) 2002; 141
Chang C. P. (ref28/cit28) 2011; 6
Mallal S. (ref3/cit3) 2002; 359
Phillips E. (ref4/cit4) 2009; 13
Mallal S. (ref2/cit2) 2008; 358
Norcross M. A. (ref13/cit13) 2012; 26
Hung S. I. (ref19/cit19) 2005; 102
Illing P. T. (ref12/cit12) 2012; 486
Almeida C. A. (ref6/cit6) 2008; 13
Saini R. V. (ref25/cit25) 2011; 186
Hetherington S. (ref1/cit1) 2001; 23
Ostrov D. A. (ref10/cit10) 2012; 109
Singer J. B. (ref21/cit21) 2010; 42
Schmidt H. (ref26/cit26) 2011; 10
Rauch A. (ref5/cit5) 2006; 43
Kindmark A. (ref22/cit22) 2008; 8
Martin A. M. (ref7/cit7) 2004; 101
Daly A. K. (ref20/cit20) 2009; 41
Chen P. (ref23/cit23) 2011; 364
Alfirevic A. (ref14/cit14) 2012; 4
Phillips E. J. (ref8/cit8) 2002; 16
Castrejon J. L. (ref16/cit16) 2010; 125
References_xml – volume: 43
  start-page: 99
  year: 2006
  ident: ref5/cit5
  publication-title: Clin. Infect. Dis.
  doi: 10.1086/504874
– volume: 41
  start-page: 816
  year: 2009
  ident: ref20/cit20
  publication-title: Nat. Genet.
  doi: 10.1038/ng.379
– volume: 8
  start-page: 186
  year: 2008
  ident: ref22/cit22
  publication-title: Pharmacogenomics J.
  doi: 10.1038/sj.tpj.6500458
– volume: 10
  start-page: 1603
  year: 2011
  ident: ref26/cit26
  publication-title: J. Proteome Res.
  doi: 10.1021/pr100967v
– volume: 186
  start-page: 3497
  year: 2011
  ident: ref25/cit25
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1003409
– volume: 101
  start-page: 4180
  year: 2004
  ident: ref7/cit7
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0307067101
– volume: 98
  start-page: 14985
  year: 2001
  ident: ref24/cit24
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.261581498
– volume: 125
  start-page: 411
  year: 2010
  ident: ref16/cit16
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2009.10.031
– volume: 42
  start-page: 1706
  year: 2012
  ident: ref11/cit11
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201142159
– volume: 19
  start-page: 97
  year: 2005
  ident: ref18/cit18
  publication-title: AIDS
  doi: 10.1097/00002030-200501030-00014
– volume: 23
  start-page: 1603
  year: 2001
  ident: ref1/cit1
  publication-title: Clin Ther.
  doi: 10.1016/S0149-2918(01)80132-6
– volume: 13
  start-page: 1
  year: 2009
  ident: ref4/cit4
  publication-title: Mol. Diagn. Ther.
  doi: 10.1007/BF03256308
– volume: 6
  start-page: e28323
  year: 2011
  ident: ref28/cit28
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0028323
– volume: 16
  start-page: 2223
  year: 2002
  ident: ref8/cit8
  publication-title: AIDS
  doi: 10.1097/00002030-200211080-00017
– volume: 26
  start-page: 21
  year: 2012
  ident: ref13/cit13
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e328355fe8f
– volume: 141
  start-page: 135
  year: 2002
  ident: ref29/cit29
  publication-title: Chem. Biol. Interact.
  doi: 10.1016/S0009-2797(02)00059-5
– volume: 109
  start-page: 9959
  year: 2012
  ident: ref10/cit10
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1207934109
– volume: 42
  start-page: 711
  year: 2010
  ident: ref21/cit21
  publication-title: Nat. Genet.
  doi: 10.1038/ng.632
– volume: 486
  start-page: 554
  year: 2012
  ident: ref12/cit12
  publication-title: Nature
  doi: 10.1038/nature11147
– volume: 364
  start-page: 1126
  year: 2011
  ident: ref23/cit23
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1009717
– volume: 13
  start-page: 281
  year: 2008
  ident: ref6/cit6
  publication-title: Antiviral Ther.
  doi: 10.1177/135965350801300202
– volume: 428
  start-page: 486
  year: 2004
  ident: ref17/cit17
  publication-title: Nature
  doi: 10.1038/428486a
– volume: 4
  start-page: 51
  year: 2012
  ident: ref14/cit14
  publication-title: Genome Med.
  doi: 10.1186/gm350
– volume: 249
  start-page: 205
  year: 2012
  ident: ref27/cit27
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2012.01147.x
– volume: 28
  start-page: 822
  year: 2008
  ident: ref9/cit9
  publication-title: Immunity
  doi: 10.1016/j.immuni.2008.04.020
– volume: 119
  start-page: 973
  year: 2007
  ident: ref15/cit15
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2006.12.617
– volume: 358
  start-page: 568
  year: 2008
  ident: ref2/cit2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0706135
– volume: 102
  start-page: 4134
  year: 2005
  ident: ref19/cit19
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0409500102
– volume: 359
  start-page: 727
  year: 2002
  ident: ref3/cit3
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)07873-X
SSID ssj0011027
Score 2.3020258
Snippet Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01....
SourceID swepub
proquest
pubmed
crossref
acs
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 759
SubjectTerms CD8-Positive T-Lymphocytes - cytology
CD8-Positive T-Lymphocytes - drug effects
CD8-Positive T-Lymphocytes - immunology
Cell Death - drug effects
Cell Line
Cell Proliferation
Clone Cells - cytology
Clone Cells - drug effects
Clone Cells - immunology
Cytokines - immunology
Dideoxynucleosides - chemistry
Dideoxynucleosides - pharmacology
Dose-Response Relationship, Drug
HLA-B Antigens - immunology
Humans
Leukocytes, Mononuclear - cytology
Leukocytes, Mononuclear - immunology
Lymphocyte Activation - drug effects
Structure-Activity Relationship
Title T‑Cells from HLA-B57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms
URI http://dx.doi.org/10.1021/tx400060p
https://www.ncbi.nlm.nih.gov/pubmed/23541086
https://www.proquest.com/docview/1353476520
https://www.proquest.com/docview/1524395724
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-96946
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3bbtQwELVKeUFCFMptKVTDrUKiaZOxnQtvYZdqQSxaiW21b5HtONKqS7Zqsm2XJ34B8Yd8CXaSTYGW8uyJJlHO2McezxlCXlAqAuGJwNGhFdWmTDpCGyLHAhQh19pLM1vgPPjk9_fZhzEfr5Dn_8jgo7dbnrFKNeToGrmOvgley3-6n9tUgTGq5Twj6iCG46V80O-P2qVHFX8uPRf45F9iodUCs7dGessynfpeyeHOvJQ76utF1car3v02udUQTIhrRNwhKzpfJ1vDWqF6sQ2j84KrYhu2YHiuXb1YJzfrYzyoq5Pukh-jn9--d_V0WoAtRIH-x9h5y4M3rvcaqvN_MDOPPcopjEcNsaq6pekU7PkuxFIocTI5hqYbEIxOZ_C-bbxbwtDwz1OxKEDkqR0wOAPrDXqWmYJcwKC58AgDbWuUJ8WX4h7Z33s36vadpo-DI2jIS0eqTFrZoEz6bqZYylPOqTK8JlSRwkxz4WYaI4mpYAxdiRl1DYIwFDRVlLv0PlnNZ7l-SEBh4CvPTDJ24xRQGqVSSFdRs0kNMoz8Dtk0Pzpp4rBIqhQ7ekn7Izrk1RIDiWpU0G0zjullps9a06Na-uMyo6dLICUmMG22ReR6NjeuKacs8Dm6V9hwZDZRiqxDHtQobF0h5cy2weqQlzUs2xGrCN6bHMSJgVoyncyTyI-Y_-h_n75BbmDVy4ObqfExWS2P5_qJYVSl3Kwi6hdSbRsc
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZgPIA0cRkwymUcEExILCPxJRfeQsfUQTtVokN9i2zHkSpKOs0pozzxFxD_kF-C7aQpjAl49klsy5_tYx-f70PoCSE84gGPPBVbUm1ChceVceRohHnMlArywiY4Dw7D3hF9M2bjhibH5sKYRmjzJ-2C-Ct2geBF9Zk68pDji-iScUKwRXPafddGDIxRzeqZEA_jeLxkEfr1U7sDSf37DvSHW3mGM9TtM_vXasEi10L3vOTD7rwSu_LLGfLG_-vCdXS1cTchrfFxA11Q5QbaHtZ81YsdGK3Sr_QObMNwxWS92EDr9aUe1LlKN9H30Y-v37pqOtVg01Kg10-9Vyx66QfPwUUDwKxD9mJHmxoVpNJpp6kc7G0vpIJL_mlyAo02EIxOZ3DQyvBWMDTe6ClfaOBlbgsM6sDWBnvWTwWxgEHz_BEGymYsT_RHfQsd7b8edXteo-rgcRKzyhOyEJZEqBChX0ias5wxIo2XE8tE4kIx7hcKJwLnnFLsC1wQ3-AJx5zkkjCf3EZr5axUdxBIHIUyMEuOPUZFhCS54MKXxBxZowInYQdtmXHImlmpMxdwx0HWDkQHPVtCIZMNJ7qV5pieZ_q4NT2uiUDOM3q0xFNmpqmNvfBSzeamasIIjQxu_b_YMExt2BTTDtqswdhWhQmjVhSrg57W6GxLLD_43uR9mhm4ZdPJPEvChIZ3_9X1h-hybzToZ_2Dw7f30BXsVD6YWTTvo7XqZK4eGF-rEltukv0EVhUjfQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1tb9MwELZgSAhp4mXAKC_jQDAhsYzEL3nhW2ipOlhHpXWo3yLbcaSK0lZLyiif-AuIf8gvwZekGYwJ-OxLzpafs88-33OEPGFMBtKTgWNCJNVmXDnSWEeOB1SGwhgvzTDBuX_g9474m5EY1QdFzIWxncjtn_IyiI9WPU-zmmHAe1F85iWByPwiuYThOkR03D5sogZWqGL2jJhDaThaMQn9-inuQjr_fRf6w7U8wxta7jXda-Rd08vyicmH3UWhdvWXMwSO_z-M6-Rq7XZCXOHkBrlgphtke1DxVi93YHiahpXvwDYMThmtlxtkvbrcgypn6Sb5Pvzx9VvbTCY5YHoK9PZj55UIXrrecyijAmDXI7zgya1GA7Eua6iZFPDWF2Iltfw0Poa6RhAMT2aw15TjLWBgvdITucxBTlNssOgD1AYd9FdBLaFfP4OEvsHM5XH-Mb9Fjrqvh-2eU1d3cCQLReEonSkkE8qU72aapyIVgmnr7YQ60jQzQrqZoZGiqeScuopmzLW4oqFkqWbCZbfJ2nQ2NXcIaBr42rNLDx6nAsaiVEnlamaPrkFGI79FtuxcJLV15kkZeKde0kxEizxbwSHRNTc6luiYnCf6uBGdV4Qg5wk9WmEqseaKMRg5NbOFVc0E44EvqPsXGUE5hk8pb5HNCpCNKsoEx-JYLfK0QmjTgjzhnfH7OLGQSybjRRL5Effv_mvoD8nlQaeb7O8dvL1HrtCy2Iewa-d9slYcL8wD63IVaqu0s5-0-CYA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=T-cells+from+HLA-B57&rft.jtitle=Chemical+research+in+toxicology&rft.au=Bell%2C+Catherine+C.&rft.au=Faulkner%2C+Lee&rft.au=Martinsson%2C+Klara&rft.au=Farrell%2C+John&rft.date=2013-05-20&rft.issn=0893-228X&rft.volume=26&rft.issue=5&rft.spage=759&rft_id=info:doi/10.1021%2Ftx400060p&rft.externalDocID=oai_DiVA_org_liu_96946
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-228X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-228X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-228X&client=summon